Diamyd Medical
About
Diamyd Medical develops precision medicine therapies to prevent and treat type 1 diabetes through innovative research and clinical development. The flagship investigational product is a precision medicine treatment under clinical evaluation, serving as a disease-modifying therapy aimed at preserving endogenous insulin production in individuals with type 1 diabetes. It is based on the autoantigen GAD65 and has received Orphan Drug Designation as well as Fast Track Designation by the U.S. FDA. Diamyd Medical’s shares are traded on Nasdaq First North Growth Market, ticker DMYD B.
SE
Kungsgatan 29, Stockholm
SE-111 56
Public Company
63
Pharmaceutical Manufacturing
Autoimune Diabetes (Type 1 Diabetes and LADA); Pre-clinical and Clinical Development; Development of Combination Therapies for the Treatment of Autoimmune Diabetes; Preserving Beta Cell Function; Pharmaceutical Development; Targeted Immunotherapy
Top Decision Makers · 11
Production Scientist
Malgorzata Wessels
Sweden
******@***.com
Phone
(**) *** ****
President & CEO
Ulf Hannelius
Sweden
******@***.com
Phone
(**) *** ****
Pharmaceutical Development Manager
Gabriella Yousef
Sweden
******@***.com
Phone
(**) *** ****
Find the Right Leads
Find Verified Contact Data
What LeadContact does well
Find verified emails, phone numbers, and decision-makers with 98% accuracy.
Find Leads
Find the right people by company, role, industry, location, and more.
925M+ professional profiles
Find Emails
Access verified email addresses for your target contacts.
657M+ emails
Find Phone Numbers
Get cross-validated phone data from multiple top sources.
239M+ phone numbers
More Accurate. Lower Cost.
Find contact data in 1 tool with 98% accuracy
LeadContact integrates leading enrichment tools to deliver more accurate contact data—without paying for each one.
Great conversations start with the right contact.
It’s time to find yours.